Trial Profile

A Parallel-group Treatment, Phase 2a, Double-blind, Placebo-controlled 2-arm Study to Show Improvement of Physical Function in SF-36 (SF-36-PF) in Participants Treated with Vericiguat Compared to Placebo Tablets in Male and Female Participants Aged 18-50 Years with Post-COVID-19 Syndrome Without (PCS) or with (PCS/CFS) Fulfillment of ME/CFS Criteria (VERI-LONG)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Jun 2025 Planned End Date changed from 30 Apr 2025 to 31 Dec 2025.
04 Jun 2025 Planned primary completion date changed from 30 Apr 2025 to 1 Oct 2025.
26 Sep 2024 Planned End Date changed from 1 Oct 2023 to 30 Apr 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com